The Motley Fool
21 Nov 2026, 00:15 UTC · 1h ago
Bristol Myers Squibb's Growth Portfolio Just Hit $7.7 Billion. Is This Cheap Pharma Stock a No-Brainer Buy?
Impact · against what's priced in
The revenue growth in Bristol Myers Squibb's new drug portfolio suggests the company can mitigate its upcoming patent cliff, making its current valuation attractive. For other listed tech names, the article provides only incidental market data that does not impact their structural valuation drivers.
- NVDA+0.00
Doesn't touch the price's assumptions
- In context
The article lists a daily price decline for Nvidia but contains no information regarding its AI hardware revenue or data center spending.





